RARE•benzinga•
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
Summary
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga